27-05-2025
Citizens JMP Sticks to Their Buy Rating for Cidara Therapeutics (CDTX)
In a report released today, Roy Buchanan from Citizens JMP maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $47.00. The company's shares closed last Friday at $24.28.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Buchanan covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Inovio Pharmaceuticals, and Arbutus Biopharma. According to TipRanks, Buchanan has an average return of -26.6% and a 26.50% success rate on recommended stocks.
Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $40.40, a 66.39% upside from current levels. In a report released on May 23, Needham also maintained a Buy rating on the stock with a $35.00 price target.
